Comprehensive management strategy of interstitial lung disease induced by trastuzumab deruxtecan

Comprehensive management strategy of interstitial lung disease induced by trastuzumab deruxtecan

Trastuzumab deruxtecan (T-DXd) has demonstrated significant efficacy in clinical trials for human epidermal growth factor receptor 2 (HER2)-expressing breast cancer, gastric cancer, lung cancer and other solid tumors. Its overall safety profile is manageable and tolerable, including the clinically c...

Full description

Saved in:
Bibliographic Details
Main Author: ZHANG Jian, HAN Qian, XU Fei, GAN Lu, CHEN Zhanhong, MA Li, WANG Hao, LIU Jieqiong, WU Xiaohong, CAI Li, ZHAO Bing, LÜ Zheng, LI Li, NI Sujie, HU Xichun
Format: Article
Language:English
Published: Editorial Office of China Oncology 2024-12-01
Series:Zhongguo aizheng zazhi
Subjects:
|interstitial lung disease|trastuzumab deruxtecan|management
Online Access:http://www.china-oncology.com/fileup/1007-3639/PDF/1737446449820-1755203622.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items